Polycystic ovary syndrome (PCOS) is an endocrine system disorder affecting between 6.5 and 8 percent of women overall.1 PCOS is a condition that can cause women to have irregular periods, grow extra facial hair, gain weight and become obese. The exact cause of PCOS is unclear but it is usually caused by excessive production of androgens by the ovaries. Most patients with PCOS are overweight or obese, with obesity being reported in 30 to 75 percent of PCOS patients. Therefore, diet and exercise to lose weight is the first-line intervention for most PCOS patients. However, due to low compliance to life style modification, drug therapies have been used to as an add-on therapy.2 Pharmacologic therapies available for the treatment of PCOS include
…show more content…
The first treatment group received metformin (n=13) 1000 mg BID. The second group received liraglutide (n=14) 1.2 mg injected subcutaneously once per day. The third group received roflumilast (n=14) 500 mcg QD. To answer the DI question, the focus will be on two of the arms, liraglutide and metformin. The primary outcome of this trial was mean change in measures of obesity and the secondary outcomes were hormonal and metabolic changes. At the start of the study, patients were given a general advice on lifestyle intervention and were instructed to report any adverse events during the treatment. Safety assessment was given at the beginning and week 4, 8 and 12 of the treatment period. Power was estimated based on data from another trial that had been done before. The author determined that in order to achieve 80% power, a sample size of 12 patients for both group would be needed. Two metformin group patients discontinued the study because of diarrhea and protocol violation. One liraglutide group patient was excluded from …show more content…
Body weight (P=0.003), whole body fat mass (P<0.001), and waist circumference (P=0.003) also showed significant reduction with both group compare to baseline, but there was no statistically significant difference between the groups. Adverse event with liraglutide were nausea and diarrhea that did not correlate with weight loss and improved over time. The author of the study concluded that liraglutide did not show statistically significant weight loss difference between metformin, but have shown to be statistically significant compare to baseline. Also from the post hoc analysis, a subgroup of patients with insulin resistance, liraglutide showed better response in patients with severe obesity and metabolic syndrome. This finding supports that the severity of metabolic instability and the degree of obesity can possibly affect the response to
The first treatment group received metformin (n=13) 1000 mg BID. The second group received liraglutide (n=14) 1.2 mg injected subcutaneously once per day. The third group received roflumilast (n=14) 500 mcg QD. To answer the DI question, the focus will be on two of the arms, liraglutide and metformin. The primary outcome of this trial was mean change in measures of obesity and the secondary outcomes were hormonal and metabolic changes. At the start of the study, patients were given a general advice on lifestyle intervention and were instructed to report any adverse events during the treatment. Safety assessment was given at the beginning and week 4, 8 and 12 of the treatment period. Power was estimated based on data from another trial that had been done before. The author determined that in order to achieve 80% power, a sample size of 12 patients for both group would be needed. Two metformin group patients discontinued the study because of diarrhea and protocol violation. One liraglutide group patient was excluded from …show more content…
Body weight (P=0.003), whole body fat mass (P<0.001), and waist circumference (P=0.003) also showed significant reduction with both group compare to baseline, but there was no statistically significant difference between the groups. Adverse event with liraglutide were nausea and diarrhea that did not correlate with weight loss and improved over time. The author of the study concluded that liraglutide did not show statistically significant weight loss difference between metformin, but have shown to be statistically significant compare to baseline. Also from the post hoc analysis, a subgroup of patients with insulin resistance, liraglutide showed better response in patients with severe obesity and metabolic syndrome. This finding supports that the severity of metabolic instability and the degree of obesity can possibly affect the response to